Advanced Proteome Therapeutics Corporation (APTCF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | - USD | 100.0% |
| 2022 | -936.55 Thousand USD | -42.11% |
| 2021 | -648.23 Thousand USD | -18.3% |
| 2020 | -547.61 Thousand USD | 38.53% |
| 2019 | -921.89 Thousand USD | 15.71% |
| 2018 | -1.09 Million USD | -2.33% |
| 2017 | -1.06 Million USD | -28.22% |
| 2016 | -833.57 Thousand USD | 36.41% |
| 2015 | -1.28 Million USD | -30.63% |
| 2014 | -961.09 Thousand USD | 4.81% |
| 2013 | -1.14 Million USD | -21.35% |
| 2012 | -883.04 Thousand USD | 14.67% |
| 2011 | -964.8 Thousand USD | 2.86% |
| 2010 | -1.04 Million USD | 3.59% |
| 2009 | -1.08 Million USD | 16.61% |
| 2008 | -1.35 Million USD | 38.89% |
| 2007 | -2.13 Million USD | -182880.96% |
| 2006 | -185.45 Thousand USD | 99.67% |
| 2005 | -355.1 Thousand USD | -213.13% |
| 2004 | -39.11 Thousand USD | -77.13% |
| 2003 | 1.37 Million USD | -37.05% |
| 2002 | 2.18 Million USD | -2.03% |
| 2001 | 2.22 Million USD | 349.06% |
| 2000 | -893.65 Thousand USD | -772.3% |
| 1999 | 66.46 Thousand USD | 120.09% |
| 1998 | -793.8 Thousand USD | -124.64% |
| 1997 | 2.68 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | - USD | 0.0% |
| 2023 Q4 | - USD | 100.0% |
| 2023 Q2 | -285.45 Thousand USD | -12.13% |
| 2023 Q1 | -254.58 Thousand USD | 0.54% |
| 2023 FY | - USD | 100.0% |
| 2023 Q3 | -147.25 Thousand USD | 48.42% |
| 2022 Q2 | -261.97 Thousand USD | -31.91% |
| 2022 FY | - USD | -42.11% |
| 2022 Q4 | -255.97 Thousand USD | -9.19% |
| 2022 Q1 | -198.61 Thousand USD | -16.85% |
| 2022 Q3 | -234.42 Thousand USD | 10.52% |
| 2021 FY | - USD | -18.3% |
| 2021 Q1 | -121.47 Thousand USD | 28.79% |
| 2021 Q2 | -187.08 Thousand USD | -54.01% |
| 2021 Q3 | -191.86 Thousand USD | -2.55% |
| 2021 Q4 | -169.97 Thousand USD | 11.41% |
| 2020 Q1 | -117.15 Thousand USD | 57.26% |
| 2020 Q3 | -136.81 Thousand USD | 3.71% |
| 2020 FY | - USD | 38.53% |
| 2020 Q4 | -170.58 Thousand USD | -24.68% |
| 2020 Q2 | -142.09 Thousand USD | -21.29% |
| 2019 Q2 | -205.42 Thousand USD | 24.22% |
| 2019 FY | - USD | 15.71% |
| 2019 Q1 | -271.06 Thousand USD | -42.05% |
| 2019 Q4 | -274.1 Thousand USD | -60.01% |
| 2019 Q3 | -171.3 Thousand USD | 16.61% |
| 2018 Q2 | -297.4 Thousand USD | -9.79% |
| 2018 Q1 | -270.89 Thousand USD | 13.02% |
| 2018 Q4 | -190.82 Thousand USD | 42.96% |
| 2018 FY | - USD | -2.33% |
| 2018 Q3 | -334.57 Thousand USD | -12.5% |
| 2017 FY | - USD | -28.22% |
| 2017 Q4 | -311.45 Thousand USD | -1.83% |
| 2017 Q3 | -305.86 Thousand USD | -19.29% |
| 2017 Q2 | -256.41 Thousand USD | -31.43% |
| 2017 Q1 | -195.09 Thousand USD | 28.97% |
| 2016 Q2 | -205.98 Thousand USD | -23.66% |
| 2016 Q3 | -186.34 Thousand USD | 9.53% |
| 2016 Q4 | -274.68 Thousand USD | -47.41% |
| 2016 Q1 | -166.56 Thousand USD | 44.2% |
| 2016 FY | - USD | 36.41% |
| 2015 Q3 | -253.51 Thousand USD | 12.25% |
| 2015 Q1 | -469.95 Thousand USD | -60.56% |
| 2015 FY | - USD | -30.63% |
| 2015 Q2 | -288.9 Thousand USD | 38.53% |
| 2015 Q4 | -298.49 Thousand USD | -17.74% |
| 2014 Q2 | -231.57 Thousand USD | -1.65% |
| 2014 Q4 | -292.69 Thousand USD | -16.55% |
| 2014 Q1 | -227.81 Thousand USD | 13.88% |
| 2014 Q3 | -251.13 Thousand USD | -8.44% |
| 2014 FY | - USD | 4.81% |
| 2013 Q1 | -264.99 Thousand USD | 11.73% |
| 2013 Q4 | -264.52 Thousand USD | 7.46% |
| 2013 Q3 | -285.86 Thousand USD | -1.37% |
| 2013 Q2 | -281.99 Thousand USD | -6.41% |
| 2013 FY | - USD | -21.35% |
| 2012 FY | - USD | 14.67% |
| 2012 Q1 | -154.33 Thousand USD | 30.11% |
| 2012 Q2 | -184.31 Thousand USD | -19.42% |
| 2012 Q3 | -229.88 Thousand USD | -24.73% |
| 2012 Q4 | -300.22 Thousand USD | -30.6% |
| 2011 Q4 | -220.83 Thousand USD | 22.44% |
| 2011 FY | - USD | 2.86% |
| 2011 Q3 | -284.73 Thousand USD | -10.62% |
| 2011 Q2 | -257.4 Thousand USD | -4.79% |
| 2011 Q1 | -245.64 Thousand USD | -57.36% |
| 2010 Q1 | -388.73 Thousand USD | -53.95% |
| 2010 Q3 | -239.74 Thousand USD | 9.14% |
| 2010 Q4 | -156.09 Thousand USD | 34.89% |
| 2010 FY | - USD | 3.59% |
| 2010 Q2 | -263.86 Thousand USD | 32.12% |
| 2009 Q2 | -268.37 Thousand USD | 15.9% |
| 2009 FY | - USD | 16.61% |
| 2009 Q3 | -247.07 Thousand USD | 7.94% |
| 2009 Q4 | -252.51 Thousand USD | -2.2% |
| 2009 Q1 | -319.12 Thousand USD | -1.69% |
| 2008 Q4 | -313.8 Thousand USD | 9.22% |
| 2008 Q1 | -337.52 Thousand USD | 76.49% |
| 2008 Q3 | -345.65 Thousand USD | -12.68% |
| 2008 Q2 | -306.77 Thousand USD | 9.11% |
| 2008 FY | - USD | 38.89% |
| 2007 Q2 | -173.38 Thousand USD | -133.42% |
| 2007 Q1 | -74.28 Thousand USD | -160.23% |
| 2007 FY | - USD | -182880.96% |
| 2007 Q4 | -1.43 Million USD | -203.99% |
| 2007 Q3 | -472.28 Thousand USD | -172.39% |
| 2006 Q4 | 123.33 Thousand USD | 336.97% |
| 2006 Q2 | -52.47 Thousand USD | -86.43% |
| 2006 Q1 | -28.14 Thousand USD | 92.52% |
| 2006 FY | - USD | 99.67% |
| 2006 Q3 | -52.04 Thousand USD | 0.81% |
| 2005 Q4 | -376.23 Thousand USD | -1171.15% |
| 2005 FY | - USD | -213.13% |
| 2005 Q1 | 48.75 Thousand USD | -79.04% |
| 2005 Q2 | -62.76 Thousand USD | -228.72% |
| 2005 Q3 | 35.12 Thousand USD | 155.96% |
| 2004 Q3 | 55.49 Thousand USD | 187.92% |
| 2004 Q1 | 88.92 Thousand USD | -65.82% |
| 2004 Q4 | 232.58 Thousand USD | 319.12% |
| 2004 FY | - USD | -77.13% |
| 2004 Q2 | -63.11 Thousand USD | -170.98% |
| 2003 FY | - USD | -37.05% |
| 2003 Q3 | 264.28 Thousand USD | 14.6% |
| 2003 Q4 | 260.15 Thousand USD | -1.56% |
| 2003 Q1 | 664.85 Thousand USD | -13.84% |
| 2003 Q2 | 214.73 Thousand USD | -65.31% |
| 2002 Q3 | 374.36 Thousand USD | 226.84% |
| 2002 Q1 | -74.5 Thousand USD | -102.76% |
| 2002 FY | - USD | -2.03% |
| 2002 Q4 | 771.63 Thousand USD | 106.12% |
| 2002 Q2 | -295.13 Thousand USD | -296.14% |
| 2001 Q1 | -243.29 Thousand USD | 56.25% |
| 2001 FY | - USD | 349.06% |
| 2001 Q4 | 2.7 Million USD | 2277.01% |
| 2001 Q3 | 113.6 Thousand USD | 139.43% |
| 2001 Q2 | -288.11 Thousand USD | -18.42% |
| 2000 Q3 | 180.15 Thousand USD | 144.3% |
| 2000 Q1 | -135.93 Thousand USD | -114.23% |
| 2000 FY | - USD | -772.3% |
| 2000 Q2 | -406.64 Thousand USD | -199.15% |
| 2000 Q4 | -556.04 Thousand USD | -408.65% |
| 1999 Q4 | 955.57 Thousand USD | 2477.94% |
| 1999 Q3 | 96.92 Thousand USD | 92.29% |
| 1999 Q2 | 8389.00 USD | -168.11% |
| 1999 Q1 | -583.12 Thousand USD | 82.01% |
| 1999 FY | - USD | 120.09% |
| 1998 Q1 | -426.04 Thousand USD | 0.0% |
| 1998 FY | - USD | -124.64% |
| 1998 Q3 | 771.92 Thousand USD | 1063.82% |
| 1998 Q2 | 66.32 Thousand USD | 115.57% |
| 1998 Q4 | -1.08 Million USD | -239.99% |
| 1997 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 100.0% |
| SQZ Biotechnologies Company | -64.14 Million USD | 100.0% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.0% |
| Mesoblast Limited | -62.38 Million USD | 100.0% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 100.0% |
| Genus plc | 73.7 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 100.0% |
| Marizyme, Inc. | -34.28 Million USD | 100.0% |
| ContraFect Corporation | -64.99 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 100.0% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 100.0% |
| Accustem Sciences Inc. | -3.74 Million USD | 100.0% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 100.0% |
| EV Biologics, Inc. | -1.26 Million USD | 100.0% |
| Q BioMed Inc. | -617.62 Thousand USD | 100.0% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 100.0% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 100.0% |
| Biomind Labs Inc. | -1.03 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Pharming Group N.V. | 9.87 Million USD | 100.0% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 100.0% |
| Skye Bioscience, Inc. | -13.54 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 100.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 100.0% |
| IMV Inc. | -35.52 Million USD | 100.0% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 100.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 100.0% |
| GB Sciences, Inc. | -1.41 Million USD | 100.0% |
| Alpha Cognition Inc. | -9.7 Million USD | 100.0% |
| HST Global, Inc. | -5303.00 USD | 100.0% |
| CSL Limited | 4.78 Billion USD | 100.0% |
| Halberd Corporation | -74.27 Thousand USD | 100.0% |
| Enzolytics Inc. | -2.12 Million USD | 100.0% |
| Resverlogix Corp. | -11.74 Million USD | 100.0% |
| Affymax, Inc. | -14.29 Million USD | 100.0% |
| SYBLEU INC | -141.57 Thousand USD | 100.0% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 100.0% |
| argenx SE | -216.02 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 100.0% |
| AVAX Technologies, Inc. | -6.11 Million USD | 100.0% |
| Zenith Capital Corp. | -8.6 Million USD | 100.0% |
| Genscript Biotech Corporation | -248.71 Million USD | 100.0% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 100.0% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Helix BioMedix, Inc. | -1.04 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 100.0% |
| BioStem Technologies, Inc. | -7.55 Million USD | 100.0% |
| ONE Bio Corp. | 13.61 Million USD | 100.0% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 100.0% |
| Burzynski Research Institute, Inc. | - USD | NaN% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 100.0% |
| Agentix Corp. | -1.37 Million USD | 100.0% |
| LadRx Corporation | 412.28 Thousand USD | 100.0% |
| Cell Source, Inc. | -4.27 Million USD | 100.0% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 1.46 Million USD | 100.0% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 100.0% |
| NovAccess Global Inc. | -1.03 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 100.0% |
| Itoco Inc. | -1.86 Million USD | 100.0% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 100.0% |
| Kadimastem Ltd | -2.62 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 100.0% |
| CytoDyn Inc. | -18.02 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 100.0% |
| Mobile Lads Corp. | -2.24 Million USD | 100.0% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 100.0% |
| Qrons Inc. | -40.08 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 100.0% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 100.0% |
| Rebus Holdings, Inc. | -951 Thousand USD | 100.0% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 100.0% |
| International Stem Cell Corporation | 202 Thousand USD | 100.0% |
| Bioxytran, Inc. | -3.82 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | -2.46 Million USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | -35.86 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | - USD | NaN% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | -45 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 100.0% |
| Neutra Corp. | -181.24 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 100.0% |
| PureTech Health plc | -11.62 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 100.0% |
| IXICO plc | -707 Thousand USD | 100.0% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 100.0% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 100.0% |
| CSL Limited | 4.73 Billion USD | 100.0% |
| Cellectis S.A. | -92.63 Million USD | 100.0% |